恒瑞医药(600276.SH)：HRS-5041片获得药物临床试验批准

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is a novel, efficient, and selective AR-PROTAC (androgen receptor-protein degradation targeting chimeric) small molecule developed by the company [1] - The drug shows significant degradation effects on both wild-type and various mutant AR proteins, with potential to overcome resistance compared to second-generation AR inhibitors [1] - The total R&D investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally [1]